VM26 therapy in children with drug-refractory lymphocytic leukemia

Gaston Rivera, Gary V. Dahl, Sharon B. Murphy, W. P. Bowman, R. J. Aur, Thomas, L. Avery, J. V. Simone

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

The information from these trials should aid in the design of future treatment strategies for leukemia patients at high risk of early relapse. Since VM26 in combination chemotherapy effectively destroyed populations of leukemia cells not susceptible to the cytotoxic activity of conventional agents, its most important future role may be in alternate remission induction treatments or perhaps as an added component of primary treatments.

Original languageEnglish
Pages (from-to)169-172
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume7
Issue number2-3
DOIs
StatePublished - Apr 1982

Fingerprint Dive into the research topics of 'VM26 therapy in children with drug-refractory lymphocytic leukemia'. Together they form a unique fingerprint.

  • Cite this

    Rivera, G., Dahl, G. V., Murphy, S. B., Bowman, W. P., Aur, R. J., Thomas, Avery, L., & Simone, J. V. (1982). VM26 therapy in children with drug-refractory lymphocytic leukemia. Cancer Chemotherapy and Pharmacology, 7(2-3), 169-172. https://doi.org/10.1007/BF00254541